The Enduring Impact of ImmunoGen’s ADC Legacy

Though ImmunoGen ceased to exist as an independent entity following its acquisition by AbbVie in February 2024, the company’s scientific contributions continue to shape oncology research. Recent developments at CytomX Therapeutics demonstrate how ImmunoGen’s pioneering antibody-drug conjugate (ADC) technology maintains significant influence across the biotech sector.

CytomX Therapeutics announced substantial clinical advancements on November 6 and 7, with their experimental therapy CX-2051 taking center stage. This investigational treatment emerged from previous collaboration with ImmunoGen, representing a direct continuation of the acquired company’s technological legacy.

Patient recruitment for the Phase 1 dose expansion study is proceeding rapidly, targeting approximately 100 participants ahead of planned data updates in the first quarter of 2026. Additionally, Read more...